Payment overview · 2025
General Payments
$112.41
6 reported records · 4 companies
Healthcare provider profile · identity verified
Deborah Ann Cross, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CONWAY, NH · NPI 1447483193
Verified facts
What the public records show
CMS Open Payments records show Deborah Ann Cross, ARNP received $112.41 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 50.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.70 | 50.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.60 | 20.1% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $18.99 | 16.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.12 | 12.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $112.41 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.35 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 181 | 35 |
| Atorvastatin Calcium | Atorvastatin Calcium | 168 | 51 |
| Losartan Potassium | Losartan Potassium | 159 | 46 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 144 | suppressed |
| Clonazepam | Clonazepam | 98 | suppressed |
| Metformin Hcl | Metformin Hcl | 89 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 81 | 20 |
| Lisinopril | Lisinopril | 74 | 21 |
| Ozempic | Semaglutide | 63 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 61 | 20 |
| Omeprazole | Omeprazole | 54 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 48 | 14 |
| Furosemide | Furosemide | 47 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 12 |
| Famotidine | Famotidine | 44 | 13 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 36 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 34 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | 12 |
| Atenolol | Atenolol | 31 | suppressed |
| Oxycontin | Oxycodone Hcl | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 24 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Eliquis | Apixaban | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 19 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Olanzapine Odt | Olanzapine | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $112.41 · 6 records | ABBVIE INC. | BREZTRI, Ozempic, UBRELVY, VIVITROL, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error